

Title: Annexin A2 Mediates Bevacizumab Resistance and Infiltrative Escape in Glioblastoma

Journal name: Journal of Neuro-Oncology

Author names: Taketo Ezaki^{1), 2)}, Ryota Tamura¹⁾, Yohei Yamamoto^{3), 4)}, Jun Takei³⁾, Akihiko Teshigawara^{3), 5)}, Kyoichi Tomoto³⁾, Yasuharu Akasaki³⁾, Yuichi Murayama³⁾, Masahiro Toda¹⁾, Hikaru Sasaki^{1), 6)}, Keisuke Miyake⁷⁾, Toshihide Tanaka^{3), 4)}

Affiliations

¹⁾ Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

²⁾ Department of Clinical Pharmacy, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan

³⁾ Department of Neurosurgery, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105-8461, Japan

⁴⁾ Department of Neurosurgery, The Jikei University West Medical Center, 4-11-1 Izumi-honmachi, Komae City, Tokyo 201-8601, Japan

⁵⁾ Department of Neurosurgery, The Jikei University Kashiwa Hospital, 163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan


⁶⁾ Department of Neurosurgery, International University of Health and Welfare Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan

⁷⁾ Department of Neurosurgery, Kagawa University School of Medicine, 1750-1 Ikenobe, Miki-cho, Kitagun, Kagawa 761-0793, Japan


e-mail address of the corresponding author: ttanaka123066@gmail.com

Supplementary Fig.S1: Association between ANXA2 expression, MRI recurrence patterns, and clinical response.

(a) ANXA2 expression associated with MRI recurrent patterns



(b) Survival outcomes based on mRANO 2.0 criteria




Supplementary Fig.S1: Association between Annexin A2 (ANXA2) expression and magnetic resonance imaging (MRI) recurrence patterns; survival outcomes based on the modified Response Assessment in Neuro-Oncology (mRANO) 2.0 criteria.

(a) ANXA2 mRNA levels were compared across three MRI recurrence patterns (cT1 flare-up, T2 circumscribed, T2 diffuse) in naïve Bev and neoBev cohorts.

(b) Kaplan-Meier analysis showed no significant PFS or OS differences among partial response (PR), stable disease (SD), and progressive disease (PD) groups categorized by mRANO 2.0.

Supplementary Fig.S2: Stratification of ANXA2 levels between high/low expression and PFS/OS



Supplementary FigureS2. Analysis of progression-free survival (PFS) and overall survival (OS) with Annexin A2 (ANXA2) mRNA expression level stratification.

Kaplan-Meier analyses of PFS and OS by median-stratified ANXA2 mRNA expression across treatment subgroups.